Frontiers in Medical Science Research, 2024, 6(7); doi: 10.25236/FMSR.2024.060712.
Xiaoqing Cai1, Jingting Lin1, Yongqing Ni2
1Department of Nephrology, People’s Hospital of Yueqing, Yueqing Hospital Affiliated to Wenzhou Medical University, Yueqing, Zhejiang, China
2Department of Gastroenterology, People’s Hospital of Yueqing, Yueqing Hospital Affiliated to Wenzhou Medical University, Yueqing, Zhejiang, China
The present study aimed to investigate the prevalence of eosinophilia (EOS) changes with the progression of renal function. Identify whether EOS is an independent risk factor in Chronic kidney disease (CKD) progression. Patients with end-stage renal disease (ESRD) experience changes in the prevalence of EOS before and after hemodialysis (HD) or peritoneal dialysis (PD). This study included 1870 CKD patients who underwent long-term hospitalization and follow-up at our nephrology department from January 2018 to December 2021. Peripheral blood eosinophil count (PBE), renal function parameters [such as creatinine, urea nitrogen, urea, estimated glomerular filtration rate (eGFR)], c-reactive protein(CRP), white blood cells, hemoglobin, and other indicators were statistically analyzed to analyze the correlation between EOS and the above indicators. The prevalence of EOS exhibited a notable increase with advancing stages of renal dysfunction, and the difference was statistically significant. The prevalence of EOS increased by 12.7% for every 1 ml/min decrease in eGFR. Progression of renal function in CKD patients is positively correlated with the prevalence of EOS. The prevalence of EOS is higher in HD patients than in non-dialysis patients.
Chronic kidney disease, Eosinophilia, End-stage renal disease, Hemodialysis, Peritoneal dialysis
Xiaoqing Cai, Jingting Lin, Yongqing Ni. Exploring the Association between Chronic Kidney Disease and Eosinophilia. Frontiers in Medical Science Research (2024), Vol. 6, Issue 7: 98-103. https://doi.org/10.25236/FMSR.2024.060712.
[1] Kanuru S, Sapra A. Eosinophilia. Treasure Island. 2023.
[2] Leukemia and Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of eosinophilia (2017). Chin J Hematol. 2017; 38: 561-565.
[3] Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol. 2001; 46: 195-208. https://doi.org/10.1016/s0039-6257(01)00261-2.
[4] Ishii R, Fujita S, Kizawa S, et al. Association between absolute blood eosinophil count and CKD stages among cardiac patients. Heart Vessels. 2016; 31: 198-205. doi: 10.1007/s00380-014-0590-8.
[5] Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013; 158: 825-830. https://doi.org/10.7326/0003-4819-158-11-201306040-00007.
[6] Fang HY, Gao JJ, Chu M. et al. Clinical Significance of Absolute Eosinophil Counts in Patients with Chronic Renal Diseases. J Clin Transfus Lab Med. 2020; 22: 148-151.
[7] Agarwal R, Light RP. Patterns and prognostic value of total and differential leukocyte count in chronic kidney disease. Clin J Am Soc Nephrol. 2011: 6:1393-1399. https://doi.org/10. 2215/CJN. 10521110.
[8] Hildebrand S, Corbett R, Duncan N, et al. Increased prevalence of eosinophilia in a hemodialysis population: Longitudinal and case control studies. Hemodial Int. 2016; 20: 414-420. https://doi.org/ 10.1111/hdi.12395.
[9] Tariq A, Okamato K, Tariq A, et al. Eosinophilia and risk of incident end stage kidney disease. BMC Nephrol. 2020; 21: 14.https:// doi: 10.1186/s12882-020-1685-3.
[10] Moledina DG, Wilson FP, Pober JS, et al. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight. 2019;4(10):e127456. https://doi: 10.1172/jci.insight.127456.
[11] Vasaitis L. IgG4-related disease: a relatively new concept for clinicians. Eur J Intern Med.. 2016; 27: 1-9. https://doi: 10.1016/j.ejim.
[12] Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease.Mod Pathol. 2012; 25: 1181-1192. https://doi: 10.1038/modpathol.2012.72.
[13] Simon P, Potier J, Thebaud HE. Facteurs de risque des réactions aiguës d'hypersensibilité en hémodialyse: enquête prospective multicentrique sur six mois dans l'Ouest de la France [Risk factors for acute hypersensitivity reactions in hemodialysis]. Nephrologie.. 1996; 17: 163-170.
[14] Kang DH, Lee Y, Kleine CE, et al. Eosinophil count and mortality risk in incident hemodialysis patients. Nephrol Dial Transplant. 2020; 35: 1032-1042. https://doi: 10.1093/ndt/gfz296.
[15] Hospers JJ, Schouten JP, Weiss ST, et al. Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. Epidemiology. 2000; 11: 261-268. https://doi.org/10.1097/00001648-200005000-00006.
[16] Hospers JJ, Rijcken B, Schouten JP, et al. Eosinophilia and positive skin tests predict cardiovascular mortality in a general population sample followed for 30 years. Am J Epidemiol. 1999: 150: 482-491. https://doi.org/10.1093/oxfordjournals.aje.a010037.
[17] Diskin CJ, Stokes TJ, Dansby LM, et al. The prevalence and meaning of eosinophilia in renal diseases on a nephrology consultation service. Nephrol Dial Transplant. 2011; 26: 2549-2558. https://doi.org/10.1093/ndt/gfq745.